Nonsense Suppression Compounds for Premature Translation Termination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases caused by nonsense mutations, such as cancer and muscular dystrophy, lack effective and safe methods to suppress premature translation termination, leading to aberrant protein production and disease progression.
Innovation Solution
Development of compounds, specifically those of Formula (1), which suppress premature translation termination by mediating the misreading of nonsense codons, allowing for the production of functional proteins and potentially treating diseases associated with nonsense mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonsense mutations are present in mRNA, then premature translation termination occurs, but functional protein production is prevented
Solution Approach 1:
The patent employs compounds that chemically modify the translation process by inducing misreading of nonsense codons. These compounds alter the physiological parameters of translation fidelity, allowing the ribosome to incorporate amino acids at premature stop codon sites, thereby converting a non-functional translation process into a functional one and enabling production of full-length proteins despite the presence of nonsense mutations
Solution Approach 2:
The invention introduces small molecule compounds as intermediaries between the nonsense codon and the translation machinery. These compounds act as mediators that facilitate the incorporation of suppressor tRNAs at nonsense codon sites, enabling the translation process to continue through the premature stop signal and produce functional protein products
2Reliability
If traditional treatment methods are used for nonsense mutation diseases, then disease progression is not effectively suppressed, but safe and effective treatment options are limited
Solution Approach 1:
The patent describes a universal approach that can be applied to multiple diseases caused by different nonsense mutations. The compounds and methods are not disease-specific but rather target the fundamental molecular defect (nonsense codon-mediated translation termination) that underlies various genetic disorders including cancers, muscular dystrophies, and other genetic diseases, thereby providing a versatile treatment platform
Solution Approach 2:
The invention converts the harmful effect of nonsense mutations (premature translation termination) into a beneficial outcome by using compounds that induce controlled misreading of these codons. Rather than attempting to correct the mutation itself, the approach exploits the misreading mechanism to enable read-through of premature stop codons, transforming a pathological feature into a therapeutic opportunity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively suppress premature translation termination, enabling the production of functional proteins, thereby treating or preventing diseases like cancer, muscular dystrophy, and other genetic disorders by promoting full-length protein expression.
Implementation Method 1
compounds, specifically those of Formula (1), which suppress premature translation termination by mediating the misreading of nonsense codons
Data Source
AI summary
The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.